BACKGROUND & AIMS: Given the limitations of conventional therapies and restrictions imposed on newer pharmacologic agents, there is an urgent need to develop efficacious and efficient treatments that teach patients behavioral self-management skills for relieving irritable bowel syndrome (IBS) symptoms and associated problems. METHODS:Seventy-five Rome II diagnosed IBS patients (86% female) without comorbid gastrointestinal disease were recruited from local physicians and the community and randomized to either 2 versions of cognitive behavior therapy (CBT) (10-session, therapist-administered CBT vs 4-session, patient-administered CBT) or a wait list control (WLC) that controlled for threats to internal validity. Final assessment occurred 2 weeks after the 10-week treatment phase ended. Outcome measures included adequate relief from pain and bowel symptoms, global improvement of IBS symptoms (CGI-Improvement Scale), IBS symptom severity scale (IBS SSS), quality of life (IBSQOL), psychological distress (Brief Symptom Inventory), and patient satisfaction (Client Satisfaction Scale). RESULTS: At week 12, both CBT versions were significantly (P < .05) superior to WLC in the percentage of participants reporting adequate relief (eg, minimal contact CBT, 72%; standard CBT, 60.9%; WLC, 7.4%) and improvement of symptoms. CBT-treated patients reported significantly improved quality of life and IBS symptom severity but not psychological distress relative to WLC patients (P < .0001). CONCLUSIONS: Data from this pilot study lend preliminary empirical support to a brief patient-administered CBT regimen capable of providing short-term relief from IBS symptoms largely unresponsive to conventional therapies.
RCT Entities:
BACKGROUND & AIMS: Given the limitations of conventional therapies and restrictions imposed on newer pharmacologic agents, there is an urgent need to develop efficacious and efficient treatments that teach patients behavioral self-management skills for relieving irritable bowel syndrome (IBS) symptoms and associated problems. METHODS: Seventy-five Rome II diagnosed IBSpatients (86% female) without comorbid gastrointestinal disease were recruited from local physicians and the community and randomized to either 2 versions of cognitive behavior therapy (CBT) (10-session, therapist-administered CBT vs 4-session, patient-administered CBT) or a wait list control (WLC) that controlled for threats to internal validity. Final assessment occurred 2 weeks after the 10-week treatment phase ended. Outcome measures included adequate relief from pain and bowel symptoms, global improvement of IBS symptoms (CGI-Improvement Scale), IBS symptom severity scale (IBS SSS), quality of life (IBSQOL), psychological distress (Brief Symptom Inventory), and patient satisfaction (Client Satisfaction Scale). RESULTS: At week 12, both CBT versions were significantly (P < .05) superior to WLC in the percentage of participants reporting adequate relief (eg, minimal contact CBT, 72%; standard CBT, 60.9%; WLC, 7.4%) and improvement of symptoms. CBT-treated patients reported significantly improved quality of life and IBS symptom severity but not psychological distress relative to WLC patients (P < .0001). CONCLUSIONS: Data from this pilot study lend preliminary empirical support to a brief patient-administered CBT regimen capable of providing short-term relief from IBS symptoms largely unresponsive to conventional therapies.
Authors: M W van Tulder; R Ostelo; J W Vlaeyen; S J Linton; S J Morley; W J Assendelft Journal: Spine (Phila Pa 1976) Date: 2000-10-15 Impact factor: 3.468
Authors: David A Shapiro; Michael Barkham; William B Stiles; Gillian E Hardy; Anne Rees; Shirley Reynolds; Mike Startup Journal: Psychol Psychother Date: 2003-09 Impact factor: 3.915
Authors: Douglas A Drossman; Brenda B Toner; William E Whitehead; Nicholas E Diamant; Chris B Dalton; Susan Duncan; Shelagh Emmott; Valerie Proffitt; Donna Akman; Karen Frusciante; Terry Le; Kim Meyer; Barbara Bradshaw; Kristi Mikula; Carolyn B Morris; Carlar J Blackman; Yuming Hu; Huanguang Jia; Jim Z Li; Gary G Koch; Shrikant I Bangdiwala Journal: Gastroenterology Date: 2003-07 Impact factor: 22.682
Authors: Jeffrey M Lackner; James Jaccard; Susan S Krasner; Leonard A Katz; Gregory D Gudleski; Edward B Blanchard Journal: Gastroenterology Date: 2007-05-21 Impact factor: 22.682
Authors: Jeffrey M Lackner; James Jaccard; Laurie Keefer; Darren M Brenner; Rebecca S Firth; Gregory D Gudleski; Frank A Hamilton; Leonard A Katz; Susan S Krasner; Chang-Xing Ma; Christopher D Radziwon; Michael D Sitrin Journal: Gastroenterology Date: 2018-04-25 Impact factor: 22.682
Authors: Brennan Spiegel; Michael Camilleri; Roger Bolus; Viola Andresen; William D Chey; Sheri Fehnel; Allen Mangel; Nicholas J Talley; William E Whitehead Journal: Gastroenterology Date: 2009-08-23 Impact factor: 22.682
Authors: Jeffrey M Lackner; Laurie Keefer; James Jaccard; Rebecca Firth; Darren Brenner; Jason Bratten; Laura J Dunlap; Changxing Ma; Mark Byroads Journal: Contemp Clin Trials Date: 2012-07-28 Impact factor: 2.226
Authors: Jeffrey M Lackner; Chang-Xing Ma; Laurie Keefer; Darren M Brenner; Gregory D Gudleski; Nikhil Satchidanand; Rebecca Firth; Michael D Sitrin; Leonard Katz; Susan S Krasner; Sarah K Ballou; Bruce D Naliboff; Emeran A Mayer Journal: Clin Gastroenterol Hepatol Date: 2013-03-21 Impact factor: 11.382